Journal
NATURE REVIEWS CLINICAL ONCOLOGY
Volume 11, Issue 6, Pages 365-376Publisher
NATURE PORTFOLIO
DOI: 10.1038/nrclinonc.2014.72
Keywords
-
Categories
Funding
- Cancer Research UK [13239] Funding Source: researchfish
- National Institute for Health Research [CL-2008-22-001] Funding Source: researchfish
- Prostate Cancer UK [PG12-49] Funding Source: researchfish
Ask authors/readers for more resources
The discovery of androgen dependence in prostate cancer in 1941 by Huggins and colleagues has remained the backbone for the treatment of this disease. However, although many patients initially respond to androgen depletion therapy, they almost invariably relapse and develop resistance with transition of the disease to a castration-resistant state. Over the past decade, the better understanding of the mechanisms that drive resistance to castration has led to the development of next-generation androgen receptor targeting agents such as abiraterone acetate and enzalutamide. This Review aims to revisit the discovery and evolution of androgen receptor targeting therapeutics for the treatment of advanced-stage prostate cancer over the years and to discuss the upcoming future and challenges in the treatment of this common cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available